News

Clinical Trials Arena1h
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...
Clinical Trials Arena21h
Clarametyx to advance trial of CMTX-101 with DMC approval
Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...
Clinical Trials Arena23h
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.